Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Sustained activity of novel THIOMAB antibody-antibiotic conjugate against Staphylococcus aureus in a mouse model: Longitudinal pharmacodynamic assessment by bioluminescence imaging.

Zhou C, Cai H, Baruch A, Lewin-Koh N, Yang M, Guo F, Xu D, Deng R, Hazenbos W, Kamath AV.

PLoS One. 2019 Oct 29;14(10):e0224096. doi: 10.1371/journal.pone.0224096. eCollection 2019.

2.

Sustained Circulating Bacterial Deoxyribonucleic Acid Is Associated With Complicated Staphylococcus aureus Bacteremia.

Gutierrez J, Guimaraes AO, Lewin-Koh N, Berhanu A, Xu M, Cao Y, Kim J, Yan D, Chang JK, Dinoso JB, Koss CA, Clemenzi-Allen A, Chambers HF, Peck MC, Baruch A, Rosenberger CM.

Open Forum Infect Dis. 2019 Feb 26;6(4):ofz090. doi: 10.1093/ofid/ofz090. eCollection 2019 Apr.

3.

A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers.

Peck M, Rothenberg ME, Deng R, Lewin-Koh N, She G, Kamath AV, Carrasco-Triguero M, Saad O, Castro A, Teufel L, Dickerson DS, Leonardelli M, Tavel JA.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02588-18. doi: 10.1128/AAC.02588-18. Print 2019 Jun.

PMID:
30910894
4.

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients.

McBride JM, Sheinson D, Jiang J, Lewin-Koh N, Werner BG, Chow JKL, Wu X, Tavel JA, Snydman DR.

Open Forum Infect Dis. 2019 Jan 14;6(2):ofz003. doi: 10.1093/ofid/ofz003. eCollection 2019 Feb.

5.

Peripheral blood gene expression predicts clinical benefit from anti-IL-13 in asthma.

Choy DF, Jia G, Abbas AR, Morshead KB, Lewin-Koh N, Dua R, Rivera P, Moonsamy P, Fontecha M, Balasubramanyam A, Santini C, Bassett E, Ray JM, Cabanski CR, Bradley MS, Maciuca R, Mosesova S, Scheerens H, Arron JR.

J Allergy Clin Immunol. 2016 Oct;138(4):1230-1233.e8. doi: 10.1016/j.jaci.2016.06.008. Epub 2016 Jun 29. No abstract available.

PMID:
27474124
6.

Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation.

Couch JA, Zhang G, Beyer JC, de Zafra CL, Gupta P, Kamath AV, Lewin-Koh N, Tarrant J, Allamneni KP, Cain G, Yee S, Ross S, Cook R, Tsai SP, Ruppel J, Ridgway JB, Paluch M, Hass PE, Franklin J, Yan M.

Clin Cancer Res. 2016 Mar 15;22(6):1469-79. doi: 10.1158/1078-0432.CCR-15-1380. Epub 2015 Nov 20.

7.

Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex.

Kolumam G, Chen MZ, Tong R, Zavala-Solorio J, Kates L, van Bruggen N, Ross J, Wyatt SK, Gandham VD, Carano RA, Dunshee DR, Wu AL, Haley B, Anderson K, Warming S, Rairdan XY, Lewin-Koh N, Zhang Y, Gutierrez J, Baruch A, Gelzleichter TR, Stevens D, Rajan S, Bainbridge TW, Vernes JM, Meng YG, Ziai J, Soriano RH, Brauer MJ, Chen Y, Stawicki S, Kim HS, Comps-Agrar L, Luis E, Spiess C, Wu Y, Ernst JA, McGuinness OP, Peterson AS, Sonoda J.

EBioMedicine. 2015 May 30;2(7):730-43. doi: 10.1016/j.ebiom.2015.05.028. eCollection 2015 Jul.

8.

Development of a safety biomarker signature to detect hepatic sinusoidal dilation associated with an anti-DLL4 biotherapeutic.

Tarrant JM, Lewin-Koh SC, Lewin-Koh N.

Biomarkers. 2014 Aug;19(5):391-401. doi: 10.3109/1354750X.2014.919026. Epub 2014 May 19.

PMID:
24842386
9.

A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection.

Auerbach MR, Yan D, Vij R, Hongo JA, Nakamura G, Vernes JM, Meng YG, Lein S, Chan P, Ross J, Carano R, Deng R, Lewin-Koh N, Xu M, Feierbach B.

PLoS Pathog. 2014 Apr 10;10(4):e1004060. doi: 10.1371/journal.ppat.1004060. eCollection 2014 Apr.

10.

Semisynthetic model calibration for monitoring glucose in mammalian cell culture with in situ near infrared spectroscopy.

Milligan M, Lewin-Koh N, Coleman D, Arroyo A, Saucedo V.

Biotechnol Bioeng. 2014 May;111(5):896-903. doi: 10.1002/bit.25161. Epub 2013 Dec 17.

PMID:
24284833
11.

A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.

Sohn SJ, Barrett K, Van Abbema A, Chang C, Kohli PB, Kanda H, Smith J, Lai Y, Zhou A, Zhang B, Yang W, Williams K, Macleod C, Hurley CA, Kulagowski JJ, Lewin-Koh N, Dengler HS, Johnson AR, Ghilardi N, Zak M, Liang J, Blair WS, Magnuson S, Wu LC.

J Immunol. 2013 Sep 1;191(5):2205-16. doi: 10.4049/jimmunol.1202859. Epub 2013 Jul 26.

12.

EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS.

Le Pichon CE, Dominguez SL, Solanoy H, Ngu H, Lewin-Koh N, Chen M, Eastham-Anderson J, Watts R, Scearce-Levie K.

PLoS One. 2013 Apr 26;8(4):e62342. doi: 10.1371/journal.pone.0062342. Print 2013.

13.

Protein microarrays for identification of novel extracellular protein-protein interactions.

Tom I, Lewin-Koh N, Ramani SR, Gonzalez LC.

Curr Protoc Protein Sci. 2013 Apr;Chapter 27:Unit 27.3. doi: 10.1002/0471140864.ps2703s72.

PMID:
23546621
14.

PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.

Choo EF, Ng CM, Berry L, Belvin M, Lewin-Koh N, Merchant M, Salphati L.

Cancer Chemother Pharmacol. 2013 Jan;71(1):133-43. doi: 10.1007/s00280-012-1988-6. Epub 2012 Oct 7.

PMID:
23053270
15.

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.

Zheng Y, Tesar DB, Benincosa L, Birnböck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ, Grimm HP, Joshi A, Justies N, Kolaitis G, Lewin-Koh N, Li J, McVay S, O'Mahony J, Otteneder M, Pantze M, Putnam WS, Qiu ZJ, Ruppel J, Singer T, Stauch O, Theil FP, Visich J, Yang J, Ying Y, Khawli LA, Richter WF.

MAbs. 2012 Mar-Apr;4(2):243-55. doi: 10.4161/mabs.4.2.19387. Epub 2012 Mar 1.

16.

Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.

Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA.

Mol Cancer Ther. 2012 Mar;11(3):752-62. doi: 10.1158/1535-7163.MCT-11-0742-T. Epub 2012 Jan 5.

17.

A secreted protein microarray platform for extracellular protein interaction discovery.

Ramani SR, Tom I, Lewin-Koh N, Wranik B, Depalatis L, Zhang J, Eaton D, Gonzalez LC.

Anal Biochem. 2012 Jan 15;420(2):127-38. doi: 10.1016/j.ab.2011.09.017. Epub 2011 Sep 21.

18.

A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis.

Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CT, Dummer W, Kelman A, Brunetta P, Lewin-Koh N, Sorani M, Leong D, Fielder P, Yocum D, Ho C, Ortmann W, Townsend MJ, Behrens TW.

Sci Transl Med. 2011 Sep 21;3(101):101ra92. doi: 10.1126/scitranslmed.3002432.

19.

Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic data.

Huang EP, Fridlyand J, Lewin-Koh N, Yue P, Shi X, Dornan D, Burington B.

BMC Cancer. 2010 Oct 27;10:586. doi: 10.1186/1471-2407-10-586.

20.

Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.

Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.

Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.

Supplemental Content

Loading ...
Support Center